ArticleFrontiers in pharmacology2025

Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies.

Maximilian Feldmüller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.